The LYO LAB app
Track every dose. Watch every vial. Pay nothing.
Log a dose in one tap, see your weeks line up, and get a heads-up before a vial runs out. Free for anyone — you don't need to buy from us to use it.
- Free for everyone
- No card needed
- Your data stays private
Your progress
Progress
12
day streak
Best: 24 days
Doses
How you feel
Tap around — this is the real app with sample data.
No catch
Free. Actually free.
Free for everyone
You don't need to be a LYO LAB customer. Anyone can sign up and use every feature.
Nothing locked
No premium tier, no trial that runs out, no feature that disappears later.
Your data stays private
Your logs belong to your account only. Nobody else sees them, and you can delete your account any time.
We make the app because it helps the people we supply. Everyone else is welcome too.
What it does
The small things it remembers for you.
Did I take it this morning?
Today shows every scheduled dose. One tap logs it.
When's the next one?
Your plan shows each peptide's days at a glance.
How much is left?
Every vial shows a fill bar and how many days it has left.
What was the concentration?
Enter your vial size and the water you added — it does the maths.
Am I keeping up?
A streak, a month grid and charts you can switch from 7 days to all time.
It's 11pm and I have a question.
A real person on WhatsApp, one tap away.
Phone, tablet or laptop
Same app, wherever you open it.
It runs in your browser, so there's nothing to install. Log on your phone in the morning, check your month on a bigger screen at night.
Monday · Sep 21
Today
Doses today
3 of 4 done
Scheduled
Semax
300 MCG · 8:00 AM
Retatrutide
2 MG · 8:00 AM
NAD+
100 MG · 9:00 AM
GHK-Cu
2 MG · 8:00 PM
Streak
This month
12 days
Best: 24 days
Doses
Your report
Your progress, in one message.
Check in each week — energy, sleep, recovery, and weight if you want. When you'd like a second pair of eyes, send the summary to us on WhatsApp. You decide what's sent, and when.
We supply and document research compounds. We don't give medical advice.